BioSpace News Archive

ImmunoGen, Inc. announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturday, March 25, at the SGO 2023 Annual Meeting in Tampa, Florida.

Hoffmann-La Roche Limited announced that on March 24, 2023 Health Canada authorized COLUMVI® for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, DLBCL arising from follicular lymphoma, or primary mediastinal B-cell lymphoma, who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy.